A detailed history of Pro Share Advisors LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 29,998 shares of ZNTL stock, worth $96,893. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,998
Previous 12,184 146.21%
Holding current value
$96,893
Previous $49,000 124.49%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.9 - $4.57 $51,660 - $81,409
17,814 Added 146.21%
29,998 $110,000
Q2 2024

Aug 13, 2024

SELL
$4.09 - $16.13 $13,300 - $52,454
-3,252 Reduced 21.07%
12,184 $49,000
Q1 2024

May 08, 2024

BUY
$10.83 - $16.49 $13,797 - $21,008
1,274 Added 9.0%
15,436 $243,000
Q4 2023

Feb 14, 2024

BUY
$9.84 - $20.13 $19,473 - $39,837
1,979 Added 16.24%
14,162 $214,000
Q3 2023

Nov 13, 2023

BUY
$19.63 - $28.29 $38,199 - $55,052
1,946 Added 19.01%
12,183 $244,000
Q2 2023

Aug 10, 2023

BUY
$17.41 - $30.05 $178,226 - $307,621
10,237 New
10,237 $288,000
Q4 2022

Feb 02, 2023

BUY
$18.07 - $25.6 $14,293 - $20,249
791 Added 7.94%
10,759 $216,000
Q3 2022

Nov 04, 2022

BUY
$20.23 - $31.73 $24,882 - $39,027
1,230 Added 14.08%
9,968 $217,000
Q2 2022

Aug 01, 2022

SELL
$17.91 - $52.25 $50,470 - $147,240
-2,818 Reduced 24.39%
8,738 $245,000
Q1 2022

May 10, 2022

SELL
$41.58 - $80.89 $116,174 - $226,006
-2,794 Reduced 19.47%
11,556 $534,000
Q4 2021

Feb 08, 2022

BUY
$66.92 - $84.79 $8,833 - $11,192
132 Added 0.93%
14,350 $1.21 Million
Q3 2021

Nov 12, 2021

SELL
$46.83 - $73.5 $85,698 - $134,505
-1,830 Reduced 11.4%
14,218 $947,000
Q2 2021

Aug 13, 2021

BUY
$37.41 - $62.25 $102,690 - $170,876
2,745 Added 20.63%
16,048 $854,000
Q1 2021

May 14, 2021

BUY
$35.69 - $52.72 $23,733 - $35,058
665 Added 5.26%
13,303 $577,000
Q4 2020

Feb 09, 2021

BUY
$31.71 - $57.97 $400,750 - $732,624
12,638 New
12,638 $656,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $184M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.